# US 12,180,266 B2 · Modified haemoglobin proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,266 B2
- Document ID: US12180266B2
- Status: Granted
- Kind: B2
- Application number: 16/493,654
- Filed: 2018-03-13
- Published: 2020-04-30
- Granted: 2024-12-31
- Earliest claimed: 2017-03-13
- Assignees: University of Essex Enterprises Limited
- Applicants: University of Essex Enterprises Limited
- Inventors: Chris E. Cooper; Brandon Reeder; Gary Silkstone
- Web page: https://patentgrep.com/patent/US12180266B2

## CPC

- C07K 14/805: Haemoglobins; Myoglobins
- A61K 38/42: Haemoglobins; Myoglobins
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to modified proteins e.g. oxygen-carrying proteins, with improved or enhanced, in comparison to a reference protein, reduction of a metal ion associated with the modified protein. The present invention also relates to methods of using such modified proteins and compositions comprising such proteins e.g. in therapy.

## Claims

### Claim 1

A human hemoglobin protein comprising at least one modified human hemoglobin beta or gamma chain subunit, wherein:
the beta chain subunit comprises SEQ ID NO:9 or 10 or the gamma chain subunit comprises SEQ ID NO:13 or 17.

### Claim 2 (depends on 1)

The protein as claimed in claim 1, wherein the modified human hemoglobin further comprises at least one modified alpha chain subunit comprising SEQ ID NO:11, 12, 14 or 16.

### Claim 3 (depends on 1)

The protein as claimed in claim 1, wherein:
the protein is conjugated to at least one protecting group, optionally wherein the at least one protecting group is at least one antioxidant enzyme or polyalkylene glycol.

### Claim 4 (depends on 1)

A multimeric protein, comprising the modified human hemoglobin beta or gamma chain subunit in claim 1; and
two modified human hemoglobin alpha chain subunits comprising SEQ ID NO:11, 12, 14 or 16.

### Claim 5 (depends on 4)

A multimeric protein as claimed in claim 4, wherein the multimer is cross-linked.

### Claim 6 (depends on 1)

A composition comprising:
a human hemoglobin protein as claimed in claim 1; and a pharmaceutically acceptable carrier or diluent.

### Claim 7 (depends on 6)

The composition as claimed in claim 6, further comprising at least one reductant, optionally wherein the at least one reductant is ascorbate.

### Claim 8 (depends on 6)

The composition as claimed in claim 6, wherein the composition is a blood substitute composition.